Hoimes Presented Promising Initial Results of Enfortumab Vedotin plus Pembrolizumab in Urothelial Cancer at ESMO 2019

“Enfortumab vedotin plus pembrolizumab has the potential to become a platinum-free option for cisplatin-ineligible locally advanced and metastatic urothelial cancer patients in the first-line setting," said Christopher J. Hoimes, DO, hematologist/oncologist at University Hospitals, assistant professor at CWRU School of Medicine, and member of the Case CCC's GU Malignancies program, at the 2019 European Society for Medical Oncology (ESMO) Congress at the end of September.

Read the full release>